参考文献
[1]Boyraz B，Sender M A，Aksoy S，et al.Trastuzumab emtansine(T-DM1)for HER2-positive breast cancer.Curr Med Res Opin，2013，29(4)：405-414.
[2]Montero A J，Escobar M，Lopes G，et al.Bevacizumab in the treatment of metastatic breast cancer：friend or foe?Curr Oncol Rep，2012，14(1)：1-11.
[3]Barton S，Swanton C.Recent developments in treatment stratification for metastatic breast cancer.Drugs，2011，71(16)：2099-2113.
[4]Dawood S，Broglio K，Buzdar A U，et al.Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment：an institutionalbased review.J Clin Oncol，2010，28(1)：92-98.
[5]Gianni L，Dafni U，Gelber R D，et al.Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer：a 4-year follow-up of a randomized controlled trial.Lancet Oncol，2011，12(3)：236-244.
[6]Goldhirsch A，Piccart-Gebhart M J，Procter M，et al.HERA trial：2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up.Cancer Res，2012，72(Suppl 24)：s103.
[7]Lumachi F，Luisetto G，Basso S M，et al.Endocrine therapy of breast cancer.Oncologist，2011，16(4)：404-414.
[8]Baselga J，Campone M，Piccart M，et al.Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer.N Engl J Med，2012，366(6)：520-529.
[9]Joensuu H，Bono P，Kataja V，et al.Update of the FINHER trial based on 5 years of follow-up.Breast，2009，18(Suppl 1)：s10.
[10]Baselga J，Cortes J，Kim S B，et al.Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer.N Engl J Med，2012，366(2)：109-119.(https://www.daowen.com)
[11]Joensuu H.HERA crosses over.Lancet Oncol，2011，12(3)：203-204.
[12]Ccsta R B，Kurra G，Greenberg L，et al.Efficacy and cardiac safety of adjuvant trastuzumab-based chemoytherapy regimens for HER2-positive early breast cancer.Ann Oncol，2010，21(11)：2153-2160.
[13]Azim H A Jr，Piccart M J.Simultaneous targeting of estrogen receptor and HER2 in breast cancr.Expert Rev Anticancer The，2010，10(8)：1255-1263.
[14]Romond E H，Perez E A，Bryant J，et al.Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.N Engl J Med.2005，353：1673-1684.
[15]Baselga J.Treatment of HER2-overexpressing breast cancer.Ann Oncol，2010，21 Suppl 7：vii36-40.
[16]Derleth C，Mayer I A.Antiangiogenic therapies in early-stage breast cancer.Clin Breast Cancer，2010，10 Suppl 1：E23-31.
[17]Slegel R，Nalshadham D，Jemal A.Cancer statistics，2012.Cancer Clin，2011，62(1)：10-29.
[18]Jones K L，Buzdar A U.Evolving novel anti-HER2 strategies.Lancet Oncol，2009，10(12)：1179-1187.
[19]DiCosimo S，Baselga J.Targeted therapies in breast cancer：where are we now?Eur J Cancer，2008，44(18)：2781-2790.